@article{552daed7894d486f830499b549e5df47,
title = "Exposure to candesartan during the first trimester of pregnancy in type 1 diabetes: experience from the placebo-controlled DIabetic REtinopathy Candesartan Trials",
abstract = "The teratogenic consequences of angiotensin-converting enzyme inhibitors angiotensin receptor blockers (ARBs) during the second and third trimesters of pregnancy are well described. However, the consequences of exposure during the first trimester are unclear, especially in diabetes. We report the experience from DIRECT (DIabetic REtinopathy and Candesartan Trials), three placebo-controlled studies designed to examine the effects of an ARB, candesartan, on diabetic retinopathy.",
keywords = "Abnormalities, Drug-Induced, Adolescent, Adult, Angiotensin Receptor Antagonists, Benzimidazoles, Diabetes Mellitus, Type 1, Diabetic Retinopathy, Female, Humans, Hypertension, Pregnancy, Pregnancy Complications, Cardiovascular, Pregnancy Outcome, Pregnancy Trimester, First, Risk Factors, Tetrazoles, Young Adult",
author = "M Porta and Hainer, {J W} and S-O Jansson and A Malm and R Bilous and N Chaturvedi and Fuller, {J H} and Klein, {Roland Blunch} and T Orchard and Parving, {Hans-Henrik Dyring} and A-K Sj{\o}lie and {DIRECT Study Group}",
year = "2011",
doi = "10.1007/s00125-010-2040-1",
language = "English",
volume = "54",
pages = "1298--303",
journal = "Diabetologia",
issn = "0012-186X",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "6",
}